Product
Help
Pricing
About
Jobs
Log in
Get started
Work
Add to collection
Aflibercept for Age-Related Macular Degeneration: A Game-Changer or Quiet Addition?
HTML
Details
Locations
Year:
2012
Type:
article
Source:
American Journal of Ophthalmology
DOI:
10.1016/j.ajo.2012.04.020
Authors:
David J. Browning,
Peter K. Kaiser,
Philip J. Rosenfeld,
Michael W. Stewart
Institutions:
Charlotte Eye Ear Nose & Throat Associates,
Cleveland Clinic,
Mayo Clinic in Florida
Language:
English
Topic:
Retinal Diseases and Treatments
Subfield:
Ophthalmology
Field:
Medicine
Domain:
Health Sciences
Keywords:
aflibercept,
age-related macular degeneration,
neovascular age-related macular degeneration,
anti-VEGF therapy,
ranibizumab,
choroidal neovascularization,
pharmacokinetics,
pro re nata dosing,
treatment frequency,
cost per patient,
visual acuity outcomes
show all 11
SDG:
Good health and well-being
Open Access status:
closed
Funders:
Research to Prevent Blindness,
Bayer,
GlaxoSmithKline,
Novartis,
Alexion Pharmaceuticals,
Carl Zeiss Meditec AG
show all 6
OpenAlex ID:
W2049825589
FWCI:
17.22
Cites:
19
Cited by:
156
Related to:
9